Abstract iASPP is a negative regulator of the apoptotic function of p53, and it can enhance the ability of hematopoietic stem cells to self-renew and resist chemo-and radiation therapy. Recent study showed that iASPP could impact the proliferation and apoptosis of leukemia cells by interacting with FHL2. However, whether they have prognostic significance in acute myeloid leukemia (AML) is unknown. Eighty-four AML patients with FHL2 and iASPP expression data from The Cancer Genome Atlas database were enrolled in the study. Patients with high expressions of FHL2 and iASPP had significantly shorter eventfree survival (EFS) and overall survival (OS) than patients with low expressions (P = 0.005, P = 0.003, respectively). Univariate analysis indicated that high expressions of FHL2 or iASPP were unfavorable for EFS and OS (all P < 0.05), while multivariate analysis confirmed that high FHL2 expression was an independent risk factor for EFS and OS (all P < 0.05). In patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, EFS and OS were not significantly different between FHL2 or iASPP high-and low-expression groups. Our results suggested that high expressions of FHL2 and iASPP were poor prognostic factors for AML, but the prognostic effect might be overcome by allo-HSCT.
Introduction
Acute myeloid leukemia (AML) is a genetically and clinically heterogeneous disease [1] . Gene mutational and expressional profile can aid the identification of different These authors contributed equally: Yang Chen, Depei Wu, Jinlong Shi, Lin Fu * Depei Wu wudepei@medmail.com.cn * Jinlong Shi jinlong_301@163.com * Lin Fu fulin022@126.com prognostic subgroups [2] . Disruption of hematopoietic stem cell (HSC) homeostasis may be one of the causes of leukemogenesis [3] . Apoptosis plays an important role in normal hematopoiesis and hematological malignancy. Reduced apoptosis of HSCs potentially contributes to the dysregulation of hematopoiesis [4, 5] . Genes in the apoptosis-stimulating proteins of p53 (ASPP) family, which are ASPP1, ASPP2 and inhibitory member of ASPP (iASPP), are key regulators of apoptosis [6] . iASPP is the most evolutionary conserved member of the ASPP family. Contrary to the other members, iASPP exhibits inhibitor effect and is a negative regulator of the apoptotic function of p53 [7] . Previous studies indicated that iASPP was highly expressed in AML and it enhanced HSCs selfrenewal and resistance to chemo-and radiation therapy [8, 9] . Recent study showed that iASPP could impact the proliferation and apoptosis of leukemia cells by interacting with four and a half LIM domains 2 (FHL2) [10] . FHL2 belongs to the FHL protein family, a subfamily of the LIM-only proteins. It is an adaptor protein involved in multiple protein complexes [11, 12] . FHL2 has been shown to be involved in several important cellular processes such as transcriptional regulation, DNA replication and signal transduction [13] . Recently, high expression of FHL2 has been associated with adverse prognosis in breast and prostate cancer, and high expression of FHL2 was found in ovarian and gastrointestinal cancer [14] [15] [16] [17] . Notably, FHL2 is also highly expressed in AML, and may play a vital role in leukemogenesis [18, 19] .
However, the prognostic roles of iASPP and FHL2 in AML remain unknown. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for AML, may reduce relapse of AML and prolong survival through significant reduction of leukemia residual disease [20] . Here we analyzed the prognostic value of iASPP and FHL2 in AML, and whether allo-HSCT could overcome their prognostic effects.
Patients and Methods

Patients
From The Cancer Genome Atlas (TCGA) database (https:// cancergenome.nih.gov/), a total of 84 AML patients with FHL2 and iASPP expression data were identified and enrolled in this study [21] . All patients underwent chemotherapy. Poor-risk patients each underwent allo-HSCT if there was no contraindication and a matched donor was available. Many intermediate-risk patients also underwent allo-HSCT. The number of patients receiving allo-HSCT was 71. Clinical characteristics at diagnosis, including peripheral blood (PB) white blood cell counts (WBC), blast percentages in PB and bone marrow (BM), French-American-British (FAB) subtypes, and the frequencies of known recurrent genetic mutations were described. Detailed descriptions of clinical and molecular characteristics were publicly accessible from the TCGA website. Event-free survival (EFS) and overall survival (OS) were the primary end points of this study. EFS was defined as the time from diagnosis to the first event, including relapse, death, absence of complete remission or the last follow-up. OS was defined as the time from diagnosis to death from any cause or the last follow-up. All patients provided informed consent, and the study protocol was approved by the Washington University Human Studies Committee.
Statistical analysis
The clinical and molecular characteristics of patients were summarized using descriptive statistics. The data sets were described with median and/or range. The numerical data were compared using the Mann-Whitney U test, and the categorical data were compared using the Χ 2 test. Survival was estimated using the Kaplan-Meier methods and log-rank test. Univariate and multivariate Cox proportional hazard models were constructed for EFS and OS, using a limited backward elimination procedure. All statistical tests were two-tailed. The level of statistical significance was set as P < 0.05. All statistical analyses were performed by SPSS software 20.0 and GraphPad Prism software 5.0.
Results
Clinical and molecular characteristics of the patients
Clinical and molecular characteristics of all patients were summarized in Table 1 . Median age was 67 (range: 22-88) years, with fifty-eight patients older than 60. Forty-five cases were men and 63 Caucasian. The median WBC count at diagnosis was 14.7 × 10 9 /L (range: 0.7-297.4 × 10 9 /L), and in 41 cases it was ≥15 × 10 9 /L. BM blast percentage was more than 70% in 46 patients and 46 had PB blasts >20%. The main FAB subtypes were M1, M2 and M4 (72.6%). Fortyfour patients had abnormal karyotypes. The percentage of good-, intermediate-and poor-risk patients were 14.6, 56.1 and 29.3%, respectively. Forty-five patients had more than five recurrent genetic mutations. NPM1 had the highest mutation frequency (n = 27, 32.1%), followed by DNMT3A (n = 23, 27.4%), FLT3 (n = 22, 26.2%), IDH1/IDH2 (n = 15, 17.9%), RUNX1 (n = 14, 16.7%), NRAS/KRAS (n = 12, 14.3%), TET2 (n = 11, 13.1%) and TP53 (n = 11, 13.1%). Thirty-one patients had AML relapse.
All patients were grouped according to FHL2 or iASPP expression levels and the clinical and molecular characteristics were compared among different groups (Table 2) . Firstly, all patients were divided into FHL2 high and FHL2 low groups by the median FHL2 expression level of the cohort. The FHL2 high group had higher WBC count (P = 0.005), lower BM blast percentage (P = 0.005), fewer FAB-M4 patients (P = 0.040), more patients with complex karyotype (P = 0.004), fewer patients with CBFβ-MYH11 (P = 0.026) and RUNX1-RUNX1T (P = 0.026), fewer good-risk (P < 0.001) and more poor-risk patients (P = 0.004) and more frequent TP53 mutations (P = 0.004) than FHL2 low group. No significant differences were found in age, gender distribution, race, PB blasts, frequency of other recurrent genetic mutations (FLT3-ITD, NPM1, DNMT3A, IDH1/ IDH2, RUNX1, NRAS/KRAS, TET2 and MLL) and relapse rates between the two groups. Secondly, all patients were divided into iASPP high and iASPP low groups by the median iASPP expression level of the cohort. Compared with iASPP low group, iASPP high group had fewer Caucasian patients (P = 0.006), fewer FAB-M4 (P = 0.040), more patients with complex karyotype (P = 0.024), fewer CBFβ-MYH11 (P = 0.026), fewer good-risk (P = 0.002) and more poor-risk patients (P = 0.010) and more frequent RUNX1 and TP53 mutations (P = 0.019, P = 0.024, respectively). No significant differences were found in age, gender distribution, WBC count, BM blasts, PB blasts, frequency of other recurrent genetic mutations (FLT3-ITD, NPM1, DNMT3A, IDH1/IDH2, NRAS/KRAS, TET2 and MLL) and relapse rates between the two groups.
Prognostic significance of FHL2 and iASPP in AML
Kaplan-Meier analysis demonstrated that high FHL2 expressers had shorter EFS and OS than the low expressers (P = 0.012, P = 0.004, Fig. 1a, b) ; high iASPP expressers also had shorter EFS and OS than the low expressers (P = 0.023, P = 0.041, Fig. 1c, d) . Then, we also found that the patients with high expressions of FHL2 and iASPP had significantly shorter EFS and OS than the patients with low expressions (P = 0.005, P = 0.003, Fig. 2a, b) . Whereas EFS and OS were not significantly different between FHL2 or iASPP high-and low-expression groups in AML patients underwent allo-HSCT (Fig. 3) . 
Uni-and multivariate analyses of EFS and OS
To assess the prognostic significance of the aforementioned clinical and molecular characteristics, we chose expression levels of FHL2 and iASPP (high vs. low), age (≥60 vs. <60 years), WBC count (≥15 vs. <15 × 10 9 /L), BM blasts (≥70 vs. <70%), FLT3-ITD (positive vs. negative) and other common genetic mutations (NPM1, DNMT3A, RUNX1 and TP53; mutated vs. wild) to construct uni-and multivariate analyses (Table 3) .
Univariate analysis indicated that multiple factors could adversely affect both EFS and OS, including high expressions of FHL2 or iASPP, age ≥ 60 years, BM blasts ≥ 70% and mutations in DNMT3A, RUNX1 and TP53 (all P < 0.05). Multivariate analysis revealed several independent risk factors for EFS and OS, including high FHL2 expression, age ≥ 60 years, WBC count ≥ 15 × 10 9 /L, BM blasts ≥ 70% and mutations in DNMT3A, RUNX1 and TP53 (all P < 0.05).
Discussion
In this study, we found that over-expressions of FHL2 and iASPP were poor prognostic factors in AML, but their adverse effects on survival were not observed in patients who underwent allo-HSCT, indicating that allo-HSCT could overcome their prognostic impact.
Previous studies showed that iASPP was overexpressed in leukemia patients [8] , downregulation of iASPP in leukemia cells could induce p53-dependent apoptosis of leukemia cells [22] , and overexpression of iASPP could increase the proliferation, self-renewal and chemotherapyresistance of HSCs [9] . High FHL2 expression was observed in AML patients with complex karyotypes [18] , and enhanced expression of FHL2 could promote cell-cycle entry of myeloid progenitor cells and increase the frequency of apoptosis of bone marrow cells [19] . Consistent with the above findings, we found that high expressions of FHL2 and iASPP were more likely to co-exist with complex /L and BM blasts ≥ 70% had unfavorable effects on EFS and OS. This was consistent with previous findings that AML in older patients generally had poorer prognosis due to higher mutation burden, poorer baseline performance status and comorbidities [23] , and that high WBC count had adverse impact on complete remission rate and survival in AML patients [24] , and abnormal proliferation of bone marrow cells had significant effects on OS [25] . Mutations in DNMT3A, RUNX1 and TP53 were also independent risk factors for EFS and OS, supported by the fact that DNMT3A mutations were associated with inferior disease-free survival and a trend towards shorter OS in cytogenetically normal AML [26] . Previous studies also demonstrated that RUNX1 mutation was a strong independent predictor for inferior OS [27] , and TP53 mutations conferred adverse prognosis in complex karyotype AML [28] . In AML patients treated with allo-HSCT, we found that expressions of FHL2 and iASPP were not correlated with EFS and OS, suggesting that their adverse prognostic effects in AML might be overcome by allo-HSCT.
Recent study [10] indicated that there were interactions between FHL2 and iASPP, and they co-localized in both nucleus and cytoplasm in leukemia cells. Knocking down either FHL2 or iASPP in K562 and Kasumi-1 cells could lead to similar effects: reduced cell proliferation, cell cycle arrest at G0/G1 phase and increased cell apoptosis. p21 and Bcl-2 signaling pathways were also involved in the regulatory mechanisms associated with FHL2 and iASPP. However, the detailed mechanism of interactions between FHL2 and iASPP, and whether other signaling pathways are involved in their interactions remain to be further studied.
In conclusion, our results indicated that high expressions of FHL2 and iASPP were poor prognostic factors for AML but could be overcome by allo-HSCT. Our study was limited by its small sample size and would require validation by larger prospective cohorts.
